Summary We have identified a high frequency of loss of heterozygosity (LOH) on the human chromosome region 8p12-p22 in a panel of microdissected familial (86% LOH) and sporadic (74% LOH) breast tumours. The two most frequently deleted regions were defined around marker D8S1 33 and in a broader centromeric region bounded by markers D8S1 37 and D8S339. We cannot unequivocally characterize the 8p12-p22 loss as an early or a late event in breast carcinogenesis. In parallel, we have performed linkage analysis in four German breast cancer families. A location score greater than 13.67 corresponding to a LOD score of 2.97 at the marker D8S137 has been obtained. Our results considerably strengthen the evidence for a breast cancer susceptibility gene(s) located on the short arm of the chromosome region at 8p1 2-p22.
1996), colon (Yaremko et al, 1994; Farrington et al, 1996) , bladder (Takle and Knowles, 1996) , liver (Emi et al, 1992) , lung (Ohata et al, 1993) , ovarian (Cliby et al, 1993) , oesophageal (Shibagaki et al, 1994) and breast cancer (Chuaqui et al, 1995; Kerangoueven et al, 1995; Imbert et al, 1996; Yaremko et al, 1996) . In several studies, the 8p losses have been mapped to two or more distinct regions in these cancers.
Deletion mapping in colorectal cancer has suggested that a region spanning 8p23.2-p22 and a more centromeric region at 8p21.3-pil .2 are lost in more than 50% of sporadic colorectal cancers (Cunningham et al, 1993; Farrington et al, 1996) . Similarly, studies in prostate cancer indicate two regions of 8p losses at 8p22 and a more proximal region at 8p2l-pl2 (Macoska et al, 1995; Bova et al, 1996; Vocke et al, 1996) . Two independent regions of loss are also supported by mapping data in the other cancers mentioned above. A common region of LOH at 8p2l.3-p22 in colon, lung and liver cancers has been described by Fujiwara et al (1994) .
Several investigations have found allelic loss of 8p to be associated with a more advanced clinical stage and invasive behaviour Received 25 October 1996 Revised 27 March 1997 Accepted 1 April 1997 Correspondence to: S Scherneck in these neoplasms (Knowles et al, 1993; Suzuki et al, 1995; Yaremko et al, 1996) . Furthermore, the metastatic potential of a rat prostatic cancer cell line as well as the tumorigenicity and invasiveness of colon carcinoma cell lines have been suppressed by introduction of a normal human chromosome 8 and the shortarm region 8pl2-pter respectively (Ichikawa et al, 1994; Tanaka et al, 1996) . Together, these data strongly suggest that one or more tumour-suppressor gene(s) involved in several epithelial neoplasms are located on 8p.
Allelic loss of 8p has not been investigated extensively in breast cancer. However, recent studies identified 8p LOH in more than 50% of sporadic breast cancers occurring in regions of 8p similar to other cancers (Kerangoueven et al, 1995; Imbert et al, 1996; Yaremko et al, 1995 Yaremko et al, , 1996 . The most frequent deleted regions were detected with markers D8S258, D8S133 and D8S259, located at 8pl2-p22 (Kerangoueven et al, 1995; Imbert et al, 1996) , but also with markers D8S254 (8p22) and NEFL (8p2l) (Yaremko et al, , 1996 . In addition, LOH in two distinct 8p areas (8pl2-p2l.3, 8p22) has been found in more than 80% of male breast cancer (Chuaqui et al, 1995) . In familial breast cancer, Lindblom et al (1993) reported 8p LOH in about 20% of familial breast tumours using markers located telomeric to those markers used by other groups.
To clarify LOH patterns on 8p in familial breast cancer, we performed LOH analysis in a large number of familial breast cancers. The same set of microsatellite markers was studied in a similar number of sporadic breast tumours for direct comparison (Dib et al, 1996; Imbert et al, 1996) . In addition, we studied a possible linkage between markers from this genomic region and breast cancer families unlinked to BRCAI and BRCA2. Tables 1 and  2 . Blood samples and tumour specimens were coded, and the confidentiality of the clinical information was preserved. The study was performed with the approval of the local ethics committee.
Tumour and blood samples
Tumour specimens from MDC families were retrieved from pathology archives. Of the 44 tumours, 27 were invasive ductal carcinoma (IDC), six were invasive lobular carcinomas (ILC) and seven were non-invasive tumours, including six ductal carcinomas in situ (DCIS) and one lobular carcinoma in situ (LCIS). Paraffin-embedded samples of human primary breast tumours and normal tissues were from consecutive patients who had undergone mastectomy at the Robert Roessle Clinic Berlin-Buch, Germany. The 50 sporadic tumours comprised 40 IDC, seven ILC, one medullary, one mucinous and one papillary carcinoma.
The pathology records of the familial and sporadic cases were reviewed by an independent pathologist and were microdissected after a modification of published procedures (Greer et al, 1994) . For each case, a representative tissue block was identified that contained the maximum density of tumour cells. An initial 4-jim pilot section was obtained, followed by ten consecutive 10-,um sections and a final 4-jm pilot section. Special care was taken to mount sections in the same orientation and without tissue distortion. The intervening sections were deparaffinized in xylene, rehydrated in descending ethanol and dried. The flanking pilot sections were stained with haematoxylin and eosin and the tumour cell-rich areas with minimal stromal component were marked. The corresponding areas on the consecutive unstained sections were isolated with a sterile hypodermic needle under a dissecting microscope and transferred into 10-50 jl of extraction buffer [1 mm Tris-HCl pH 7.5, 1% (v/v) Triton X100]. The suspension was supplemented with 5-25 jl of proteinase K (20 mg ml-'; Boehringer Mannheim, Germany) and digested at 37°C for a minimum of 16 h followed by heat inactivation of the enzyme at 99°C for 10 min. Similarily, non-tumorous DNA was extracted from tumour cell-free adjacent tissue or lymph nodes. Between 1 and 5 jl of the extraction volume was used for subsequent detection of LOH.
EDTA blood samples were obtained for the extraction of genomic DNA, which was isolated from whole blood by standard procedures.
Detection of LOH The oligonucleotide primers for the seven polymorphic markers used in this study were synthesized according to published primer sequences (GDB; Kerangoueven et al, 1995; Dib et al, 1996) . Polymerase chain reactions (PCR) were carried out with 40 ng of (Figure 1 ).
Statistical analysis was performed using a x2 (Fisher exact) test, with P values <0.05 considered to be statistically significant.
Linkage analysis
Microsatellite typing was performed using standard procedures. To establish the probability that a family was linked to BRCAJ, allelotyping was performed using the BRCAJ flanking or intragenic microsatellite markers D17S250, D17S588 and D17S579. Linkage to BRCA2 was assessed using the chromosome 13 markers D13S289, D13S260 and D13S267. Linkage analysis for 8pl2-p22 was performed using the seven markers described in the text.
The penetrance and gene frequencies are based on the CASH model (Claus et al, 1991 (Claus et al, , 1993 .
Linkage calculations were performed using the program MLink of Fastlink (Cottingham et al, 1993) and Vitesse (O'Connel et al, 1995) .
RESULTS

Identification of loss of heterozygosity in familial and sporadic breast tumours
A total of 44 familial breast tumours from 29 different families and 50 sporadic breast tumours were examined for LOH with seven polymorphic microsatellite markers covering the chromosome region 8pl2-p22. The order of the markers, i.e. D8S133, NEFL, D8S131, D8S137, D8S339, D8S259 and D8S505, was derived from existing consensus maps and the most recent literature (Spurr et al, 1995; Dib et al, 1996; Imbert et al, 1996; Yu et al, 1996) . All cases were informative for at least one marker. Overall, 86.4% of informative familial and 74% of informative sporadic tumours showed LOH for at least one marker on chromosome region 8pl2-p22. The results of the LOH analysis are presented in Figure   2A and B and Tables 3 and 4. The most frequently deleted region in familial breast cancer was observed with markers D8S 133 in the telomeric region (52% LOH) and with markers covering the central part of 8pl2-p22 at D8S131 (52% LOH), D8S137 (54% LOH) and D8S399 (48% LOH), ( Figure 2C and Table 4 ). Familial breast tumours were also analysed for LOH at BRCAI and BRCA2 markers. Of the informative cases, 64.7% and 50.0% showed LOH in these chromosomal regions encompassing BRCAJ and BRCA2 respectively (Table 3) . Interestingly, a number of tumours showed concomitant allelic loss of all three chromosomal regions (8pl2-p22, 17q21 and 13q13).
In sporadic breast tumours, the most frequent losses involved the telomeric markers D8S133 (48% LOH) and NEFL (41% LOH), followed by the marker D8S137 (45% LOH) and the more centromeric marker D8S339 (39% LOH) ( Figure 2B and C, Table 4 ). In comparison to the sporadic cancers, familial tumours showed a similar pattern of loss, yet at a frequency of up to 17% higher (for marker D8S 131) than the sporadic cases.
Linkage analysis of breast cancer families with chromosome region 8p12-p22 microsatellite markers
The high frequencies of LOH detected at microsatellite loci from the chromosomal region 8pl2-p22 in familial and, to a lesser extent, sporadic breast tumours prompted a focused linkage analysis. Of the 48 German families collected in the course of a nationwide project (Zimmermann et al, 1993; Jandrig et al, 1996) , 12 yielded negative LOD scores for markers within or closely linked to the BRCAJ and BRCA2 genes (Table 5) . These twelve families, likely to be unlinked to either BRCA1 and BRCA2, were selected for genetic linkage analysis using tie three 8pl2-p22 markers D8S133, NEFL and D8S259, which showed the highest percentage of LOH (Table 4) . A Linkmap-multipoint linkage yielded a positive LOD score for these markers in four of the twelve families (families 20, 59, 60 and 81) (Figure 3 and Table 5 ).
Extending the linkage analysis to D8S 137, D8S131 and D8S339 produced a location score greater than 13.67, corresponding to a LOD score of 2.97 (Figure 2) . A single peak was observed at markers D8S137/D8S131 flanking a nadir at D8S339, which is due to a recombination event in family 60 (individual 415).
These linkage data provide further support for a novel breast cancer susceptibility locus located to the approximately 20-cM interval between NEFL and D8S505 (Kerangouven et al, 1995; Imbert et al, 1996) .
Correlation of clinical and histopathological parameters with 8p12-p22 allelic loss in familial breast cancer
The 44 microdissected familial tumours included seven noninvasive (NIC) and 37 invasive carcinomas (IC), thus allowing the investigation of the relation of 8p deletions to the state of invasiveness. All tumours were informative for at least one 8p marker. All non-invasive carcinomas (7 out of 7, 100%) and 31 of the 37 invasive carcinomas (83.8%) showed LOH with one or more 8p marker, a difference not statistically significant at the P < 0.975 level. This trend could suggest a preferential involvement of 8p LOH in tumours progressing towards invasion via an intraductal stage, whereas primary invasive cancers may at least partly depend on somatic events not involving the short arm of chromosome 8.
With regard to histotypes, 22 of the 27 invasive ductal carcinomas (81.5%) and all of the invasive lobular carcinomas (7 out of 7, 100%) showed LOH with at least one marker, a difference not statistically significant at the P < 0.9 level. Again, this trend may suggest that 8p loss is potentially involved in the determination of the tumour growth pattern.
There was no correlation between 8p LOH and tumour size, grade, ER status, overall and disease-free survival, age of onset of the breast cancer or presence of metastases (all P > 0.1). Also, no correlation was found between 8p LOH and the presence of LOH around BRCAJ, BRCA2 or both.
We have divided the breast cancer families into groups, according to the type of tumours observed: breast cancer-only families (BC), families with breast and ovarian cancer (BOC) and families with various other cancers in addition to breast cancer (VOC). All the tumours from the five BC families (9 out of 9; 100%) showed 8p LOH with at least one marker, whereas 29 of the 35 (82.8%) breast carcinomas from 24 VOC families demonstrated 8p deletions. In the BOC families, the only tumour studied displayed 8p LOH. Although the number of losses in the family groups was too small to give significant results by X2 analysis (P > 0.7), a trend towards a predominance of 8p losses in BC families is apparent.
British Journal of Cancer (1997) 76(8) (Suzuki et al, 1995) , colon (Tanaka et al, 1996) , bladder (Knowles et al, 1993) and hepatoLoss n Informative, no loss Not informative cellular (Emi et al, 1992) carcinoma. In breast cancer, the results of such studies have been few and are rather contradictory. C Yaremko et al (1995) (Yaremko et al, 1996) .
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It has been suggested that LOH in familial tumours could, to a greater extent, involve regions likely to harbour tumour-predis-0 D8S133 NEFL D8S131 D8S137 D8S339 D8S259 D8S505 posing genes and, to a lesser extent, genes involved in tumour progression (Lindblom et al, 1993 Imbert et al, 1996) . These data were based mainly on
The two most frequently deleted regions in familial tumours cumulative linkage analysis of eight French families, whose indiwere located at marker D8S133 (8p2l.1-pter) and more vidual LOD scores did not significantly exceed 0.5 for NEFL and centromerically between D8S137 and D8S339 (Figure 1) . In D8S259. In our analysis, the maximum multipoint LOD score of sporadic tumours, a similar pattern of loss was observed.
2.32 was obtained at 0 = 0.00 for family 60 (Seitz et al, 1997) . (Yu et al, 1996) . Furthermore, Bruskiewich et al (1996) genetically mapped the gene for the luteinizing hormone-releasing hormone (LHRH) to a region bounded proximally by D8S137 and distally by D8S136. LHRH is a key neuroendocrine molecule in the hypothalamic-pituitary-gonadal hormonal system and impaired function of this hormone may also influence tumour cell proliferation (Irmer et al, 1995; Bruskiewich et al, 1996) .
Whether these or another as yet unknown gene on chromosome band 8pl2-p22 will prove to be the putative breast cancer susceptibility gene(s) remains to be elucidated.
